Skip to content
You are now leaving to visit

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

Ionis earns $5 million license fee from Dynacure CARLSBAD, Calif. and STRASBOURG, France , Nov. 9, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5 Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2